Početna › Astrocitom › Illinois
Kliničke studije za Astrocitom u državi Illinois
9 studija za Astrocitom traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
Službeni tekst studije (engleski)
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- i još 18
U tijeku regrutacijaFaza 3
Od 12 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07215910A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT05765812Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
U tijeku regrutacijaOpažajna studija
12 Months – 39 Years · Oba spola · Ažurirano 8. ruj 2026. · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
U tijeku regrutacijaFaza 2
Od 12 do 39 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 do 130 godina · Oba spola · Ažurirano 12. kol 2026. · NCT05417594Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
U tijeku regrutacijaRana faza 1Zdravi dobrovoljci dobrodošli
Od 1 do 21 godina · Oba spola · Ažurirano 29. lip 2026. · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
U tijeku regrutacijaFaza 2
12 Months – 39 Years · Oba spola · Ažurirano 29. svi 2026. · NCT05843253Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.